Theralase Technologies specializes in advanced medical technologies aimed at treating cancer and pain management through innovative therapies. Their Anti-Cancer Therapy (ACT) utilizes patented light-activated Photo Dynamic Compounds (PDCs), specifically TLD-1433, which target cancer cells by exploiting their higher absorption rates of transferrin, a glycoprotein that facilitates iron uptake. When activated by light, TLD-1433 generates reactive oxygen species that induce cell death in cancerous tissues, offering a promising treatment option for conditions like Non-Muscle Invasive Bladder Cancer (NMIBC). The company has conducted clinical studies demonstrating the safety and efficacy of this approach, with ongoing research aimed at further validating its therapeutic potential.

In addition to their cancer treatment technologies, Theralase also offers Cool Laser Therapy (CLT), which employs proprietary medical laser systems to alleviate pain, particularly in knee conditions. This therapy is designed for both human and animal applications, showcasing the versatility of their laser systems. The TLC-2000 Laser Series is one of the key products in this line, providing practitioners with tools to deliver effective pain relief through bio-stimulation. Theralase's commitment to research and development is evident in their extensive pipeline and clinical studies, which aim to enhance the effectiveness of their therapies and expand their applications in the medical field.

Canada

Theralase® is focused on the design, development, manufacturing, and sale of patented laser technology platforms used in a wide range of bio-stimulative and bio-destructive applications. The company is a Canadian clinical stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds (PDCs) for the treatment of various cancers. Theralase® was one of the first companies in North America to develop personalized anti-cancer therapy and cool laser therapy.

Theralase Technologies

Company Details